The WHO late Wednesday night revoked the temporary pause it had ordered last week on the hydroxychloroquine arm of the ongoing Solidarity Trial and announced the trial to resume.
The decision followed the recommendations of the Data Safety Board of the WHO that reviewed mortality trends and concluded that there was no cause to modify any arm of the Solidarity Trial protocol which is underway to test four drugs for efficacy against COVID 19.
Indian scientists stood vindicated after the WHO decision as the ICMR has decided to continue using HCQ for prevention of COVID in health workers and frontline staffers.
WHO said in a statement on Wednesday night, 'The Executive Group received the recommendation of the Data Safety Board and endorsed continuation of all arms of the Solidarity Trial, including hydroxychloroquine.
The Executive Group will communicate with the principal investigators in the trial about resuming the hydroxychloroquine arm of the trial.'
The world body said the Data Safety and Monitoring Committee will continue to closely monitor the safety of all therapeutics being tested in the Solidarity Trial.